Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunityResearch in context

Authors: James I. Robinson, Md Yuzaiful Md Yusof, Vinny Davies, Dawn Wild, Michael Morgan, John C. Taylor, Yasser El-Sherbiny, David L. Morris, Lu Liu, Andy C. Rawstron, Maya H. Buch, Darren Plant, Heather J. Cordell, John D. Isaacs, Ian N. Bruce, Paul Emery, Anne Barton, Timothy J. Vyse, Jennifer H. Barrett, Edward M. Vital, Ann W. Morgan

Source: EBioMedicine, Vol 86, Iss , Pp 104343- (2022)

Subject Terms: Autoimmune diseases, B-lymphocytes, Genetics, Rheumatoid arthritis, Rituximab, Systemic lupus erythematosus, Medicine, Medicine (General), R5-920

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2352396422005254; https://doaj.org/toc/2352-3964

Access URL: https://doaj.org/article/737647859b7c4fa4b27b129f6871d9c8

A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis

Authors: Jack Arnold, Edward M. Vital, Shouvik Dass, Aamir Aslam, Andy C. Rawstron, Sinisa Savic, Paul Emery, Md Yuzaiful Md Yusof

Source: Frontiers in Immunology, Vol 12 (2022)

Subject Terms: B cell, rituximab, cyclophosphamide, immunoglobulin, vasculitis, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2021.803175/full; https://doaj.org/toc/1664-3224

Access URL: https://doaj.org/article/a4e04aba48d646c89c46ddaebab40462

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial

Authors: Jamie B. Oughton, Laura Collett, Dena R. Howard, Anna Hockaday, Talha Munir, Kathryn McMahon, Lucy McParland, Claire Dimbleby, David Phillips, Andy C. Rawstron, Peter Hillmen

Source: Trials, Vol 18, Iss 1, Pp 1-12 (2017)

Subject Terms: Chronic lymphocytic leukaemia (CLL), Obinutuzumab, GA-101, Consolidation, Phase II/III trial, Minimal residual disease (MRD), Medicine (General), R5-920

File Description: electronic resource

Relation: http://link.springer.com/article/10.1186/s13063-017-2107-0; https://doaj.org/toc/1745-6215

Access URL: https://doaj.org/article/85a3ae6118144f27ac5415aae69c87c7

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen

Authors: Ruth M. de Tute, Andy C. Rawstron, Walter M. Gregory, J. Anthony Child, Faith E. Davies, Sue E. Bell, Gordon Cook, Alexander J. Szubert, Mark T. Drayson, Graham H. Jackson, Gareth J. Morgan, Roger G. Owen

Source: Haematologica, Vol 101, Iss 2 (2016)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://haematologica.org/article/view/7642; https://doaj.org/toc/0390-6078; https://doaj.org/toc/1592-8721

Access URL: https://doaj.org/article/60d5de834006459097fe542a146e6694

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

Authors: Andy C. Rawstron, Alberto Orfao, Meral Beksac, Ludmila Bezdickova, Rik A. Brooimans, Horia Bumbea, Klara Dalva, Gwenny Fuhler, Jan Gratama, Dirk Hose, Lucie Kovarova, Michael Lioznov, Gema Mateo, Ricardo Morilla, Anne K. Mylin, Paola Omedé, Catherine Pellat-Deceunynck, Martin Perez Andres, Maria Petrucci, Marina Ruggeri, Grzegorz Rymkiewicz, Alexander Schmitz, Martin Schreder, Carine Seynaeve, Martin Spacek, Ruth M. de Tute, Els Van Valckenborgh, Nicky Weston-Bell, Roger G. Owen, Jesús F. San Miguel, Pieter Sonneveld, Hans E. Johnsen

Source: Haematologica, Vol 93, Iss 3 (2008)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://haematologica.org/article/view/4784; https://doaj.org/toc/0390-6078; https://doaj.org/toc/1592-8721

Access URL: https://doaj.org/article/17a5bf9d8e054557b585a0945df8838f

Translocation t(11;14) in multiple myeloma: Analysis of translocation breakpoints on der(11) and der(14) chromosomes suggests complex molecular mechanisms of recombination.

Authors: James A. L. Fenton, Guy Pratt, Dominic G. Rothwell, Andy C. Rawstron, Gareth J. Morgan

Source: Genes, Chromosomes & Cancer; Feb2004, Vol. 39 Issue 2, p151-155, 5p

Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial

Authors: Dena R Howard, Talha Munir, Lucy McParland, Andy C Rawstron, Anna Chalmers, Walter M Gregory, John L O’Dwyer, Alison Smith, Roberta Longo, Abraham Varghese, Alexandra Smith, Peter Hillmen

Source: Health Technology Assessment, Vol 21, Iss 28 (2017)

Subject Terms: chronic lymphocytic leukaemia, randomised controlled trial, cost-effectiveness analysis, toxicity, fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab, Medical technology, R855-855.5

File Description: electronic resource

Relation: https://doaj.org/toc/1366-5278; https://doaj.org/toc/2046-4924

Access URL: https://doaj.org/article/03938ff7492b4c218f74b239ad351a68